- Home
- ATXS
as 10-03-2025 4:00pm EST
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 424.4M | IPO Year: | 2015 |
| Target Price: | $33.00 | AVG Volume (30 days): | 436.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.56 - $12.52 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -74.39% |
Latest Astria Therapeutics Inc. News
ATXS Breaking Stock News: Dive into ATXS Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy?
Business Wire
4 months ago
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
Business Wire
4 months ago
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
Business Wire
4 months ago
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
Business Wire
4 months ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
4 months ago
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference
Business Wire
4 months ago
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
Business Wire
4 months ago
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Compare ATXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATXS Astria Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.